Health and Fitness Health and Fitness
Wed, March 6, 2013
[ Wed, Mar 06th 2013 ] - Market Wire
Alchemia Granted Key US Patent
Tue, March 5, 2013
Mon, March 4, 2013
Sun, March 3, 2013
Sat, March 2, 2013
Fri, March 1, 2013
Thu, February 28, 2013
Wed, February 27, 2013
Tue, February 26, 2013
Mon, February 25, 2013
Sun, February 24, 2013
Sat, February 23, 2013
Fri, February 22, 2013
Thu, February 21, 2013
[ Thu, Feb 21st 2013 ] - Market Wire
Inorganic Growth of Healthcare
Wed, February 20, 2013
Tue, February 19, 2013
Mon, February 18, 2013
Sun, February 17, 2013
Fri, February 15, 2013
Thu, February 14, 2013
Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013

Advanced Proteome Therapeutics Corp. (APC) Announces New Directions in Cancer Therapies


//health-fitness.news-articles.net/content/2013/ .. nnounces-new-directions-in-cancer-therapies.html
Published in Health and Fitness on Monday, February 25th 2013 at 5:30 GMT by Market Wire   Print publication without navigation


February 25, 2013 08:26 ET

Advanced Proteome Therapeutics Corp. (APC) Announces New Directions in Cancer Therapies

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 25, 2013) -

Preparation and testing of innovative, homogeneous drugs: combining multiple therapies by linking them to a protein which is directly targeted to cancer tumors and has been shown to promote anti-tumor immunity. The Advanced Protein Conjugate Therapeutic (APCT).

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) announces that the successful development of pioneering enabling technology designed to link small entities to specific sites on proteins, has allowed APC to begin the process of applying the technology to proteins targeted to cancers. Advanced, targeted therapies are intended to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future.

The Company's technology is based on a proprietary platform that can be used to attach known therapeutic entities to specific sites on proteins; in this case, a protein which not only has shown affinity for specific cancer cells in a broad range of studies, but also has been demonstrated to promote anti-tumor immunity in animal testing. The attachments are designed to enhance the properties of this protein targeted for cancer cells and endow it with additional therapeutic functions. The basis of APC's technology is what the Company regards as the Foundation Trinity: consisting of not only targeted therapy and combination therapy, but homogeneous therapy as well. Homogeneity originates from the utilization of this protein not only as a delivery system, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein, key to efficient manufacturing and product development. This latter feature differentiates APC from its competitors and affords competitive advantages in homogeneously producing single agents bearing multiple therapies that meet the industrial gold standard of purity.

Over the near term, the Company has made the targeted delivery of anti-cancer drugs to tumor cells its point of focus. This program will involve the following steps and milestones:

  1. APC plans on synthesizing a number of the aforementioned multicomponent anticancer agents using its patent-pending technology. This effort has begun.
  2. Contracts will be sought with expert scientists at cutting edge laboratories to perform the testing. This effort has begun.
  3. Once fully executed agreements are in place, the first round of testing will begin-agents will be screened for their ability to target cancer cells specifically and for any obvious toxic effects on healthy cells.
  4. In the second round of testing, any promising agents will undergo animal testing to determine the potency and toxicity of the agent against animal models. To the extent possible, a determination of the effectiveness of the APCT in both killing cancer cells with attached chemotherapeutics as well as harnessing the immune system to specifically target tumor cells will be attempted.

The Company anticipates the completion of the above milestones over the next six months.

In summary, APC will seek to forge a new direction that we hope will change the way cancers are treated. The classical concept of a drug as a magic bullet for treating disease, which has underlain R&D since the turn of the 20th century, has evolved to favor simultaneous use of a more diverse and complex arsenal of weapons to meet the challenges of cancer. By analogy, APC expects to implement a strategy that extends the magic bullet concept to a multiple warhead concept in the War on Cancer.

About APC

APC specializes in the development and patenting of advanced methods and platform technologies designed to deliver drugs to specific cellular targets. The Company's patent-pending technology creates transportation systems for drugs to target cells that need to be destroyed, such as cancer cells. APC uses its proprietary enabling technology for chemical modification of the carrier proteins. These methods allow the drug, in accord with regulatory requirements, to be site-specifically attached to the carrier protein which tracks to cancers cells. APC is focused on developing the first commercial application of cancer cell targeting by a specific protein family that has a homing instinct for cancer cells. Due to its high affinity for a target receptor on cancer cells, the protein can function as a transport system for drugs linked to its surface, with the prospect of avoiding the debilitating toxic effects that have plagued the use of chemotherapeutic drugs.

By virtue of a similar homing instinct of the protein family for cells in the process of dying, the foregoing technologies are also applicable to the repair of cells where loss of function is a critical event, such as in eye diseases and myocardial infarction.

ON BEHALF OF THE BOARD

Alexander (Allen) Krantz, President and Chief Executive Officer

The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.




Publication Contributing Sources